Bolt Biotherapeutics (NASDAQ: BOLT) reported a net loss of $7.7 million for the second quarter ended June 30, 2026, driven by a near-total collapse in collaboration revenue and ongoing research costs. Earnings per share (EPS) came in at $(4.57), widening from $(4.46) in the same period last year. The clinical-stage biopharmaceutical company disclosed that its cash balance of $18.1 million is expected to fund operations into the first quarter of 2027, providing a runway for its lead program BDC-4182 to reach key clinical milestones.

The financial deterioration was primarily fueled by a 99.7 percent year-over-year drop in collaboration revenue, which fell to just $5,000 compared to $1.8 million in Q2 2025. This drastic decline reflects the fulfillment of performance obligations under previous R&D collaborations with partners Genmab and Toray. Despite the revenue collapse, the company managed to reduce its operating expenses through restructuring efforts. Research and development (R&D) expenses decreased to $5.1 million from $7.5 million, while general and administrative (G&A) expenses fell to $2.4 million from $3.5 million. These reductions were attributed to lower salary-related costs and decreased consulting fees.

Key Financial Metrics

Clinical Progress and Cash Position

While commercial activity has effectively ceased, Bolt Biotherapeutics is advancing its lead candidate, BDC-4182, a next-generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) targeting claudin 18.2. The Phase 1/2 study in patients with gastric and gastroesophageal cancer is currently treating patients in Cohort 4 at the 4.0 mg/kg dose level. President and Chief Executive Officer Willie Quinn stated that the compound has been well tolerated and is showing activity consistent with its immune-stimulating mechanism. Initial clinical data from this study is expected to be released alongside the company’s third-quarter 2026 results.

The company’s balance sheet reflects a strategic drawdown of resources. Total assets decreased to $40.3 million as of June 30, 2026, from $56.7 million at the end of 2025. This reduction includes a significant decrease in short-term investments, which fell to $4.7 million from $15.8 million, as capital was utilized to fund operations. Interest income, net, dropped to $178,000 from $599,000 in the prior year quarter, further reducing the offset against operational losses.

What the Numbers Show

The divergence between the modest narrowing of the net loss ($7.7 million vs $8.6 million) and the catastrophic decline in revenue highlights the effectiveness of Bolt Biotherapeutics’ cost-cutting measures. By reducing R&D and G&A expenses by over $2.5 million combined, the company mitigated what would have been a much wider deficit given the loss of nearly all collaboration income. However, the reliance on interest income and other non-operating gains, which totaled $654,000, remains a critical factor in cushioning the bottom line. With no significant revenue generation expected until potential future collaborations or licensing deals are secured, the company’s ability to sustain operations depends entirely on its remaining cash reserves and the successful progression of BDC-4182 to justify further investment or partnership opportunities.